Pharmaceutical - Markets & Marketing, Rare diseases

Filter

Popular Filters

1 to 25 of 30 results

Ipsen takes step forward in the resupply of Increlex for the USA

Ipsen takes step forward in the resupply of Increlex for the USA

13-05-2014

Following previous availability problems, French drugmaker Ipsen said today that a supply of Increlex…

IncrelexIpsenMarkets & MarketingPharmaceuticalProductionRare diseasesUSA

Marken ready for orphan drug distribution

24-04-2014

USA-based Marken, a global clinical supply chain solutions provider, has released a new white paper which…

Markets & MarketingPharmaceuticalProductionRare diseases

Jazz Pharma and Gentium debut Defitelio in Europe

31-03-2014

Ireland-headquartered Jazz Pharmaceuticals and its Italian subsidiary Gentium have initiated the European…

AustriaDefitelioEuropeGentiumGermanyJazz PharmaceuticalsMarkets & MarketingPharmaceuticalRare diseases

Which place for orphan drugs in the strategy of pharma companies and payers?

27-02-2014

As the 7th Rare Disease Day will be held on February 28, ALCIMED, an innovation and new business consulting…

Markets & MarketingNovartisPharmaceuticalPricingRare diseasesResearchRocheSanofi

US orphan drug market outlook 2018: Report

25-02-2014

In the largest market for orphan drugs, the USA, there was a shortage of adequate therapies for treating…

Markets & MarketingNorth AmericaPharmaceuticalRare diseasesRegulationUSA

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

18-12-2013

French drugmaker Ipsen says that Lonza has successfully re-manufactured the active ingredient of Increlex…

Anti-Arthritics/RheumaticsEuropeGastro-intestinalsIncrelexIpsenLonzaMarkets & MarketingMayoly SpindlerPharmaceuticalProductionRare diseases

Daiichi Sankyo launches Biopten Granules 10% in Japan

Daiichi Sankyo launches Biopten Granules 10% in Japan

29-11-2013

Japanese drug major Daiichi Sankyo has launched natural tetrahydrobiopterin agent Biopten Granules 10%…

Asia-PacificBioptenDaiichi SankyoMarkets & MarketingPharmaceuticalRare diseases

Eisai's new Belgium operation to help firm's globalization aims

16-09-2013

Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of Japanese drug major Eisai…

EisaiEuropeHalavenInovelonMarkets & MarketingOncologyPharmaceuticalRare diseases

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Protalix BioTherapeutics enters Gaucher drug Uplyso deal with Brazil's Ministry of Health

19-06-2013

Israel-based Protalix BioTherapeutics (TASE:PLX) has entered into a supply and technology transfer agreement…

FiocruzMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesSouth AmericaUplyso

Orphan diseases' appeal lies in return on investment, says Evaluate

24-04-2013

For many years, Big Pharma's model of success has been the blockbuster: drugs that sell more than $1…

BiotechnologyFinancialMarkets & MarketingPharmaceuticalRare diseasesResearch

Roche and Isis Pharma in up to $392 million deal on Huntington's research

09-04-2013

Swiss drug major Roche (ROG: SIX) and USA-based Isis Pharmaceuticals (Nasdaq: ISIS) have formed an alliance…

Isis PharmaceuticalsLicensingMarkets & MarketingPharmaceuticalRare diseasesResearchRoche

Global orphan drugs market led by Roche's rituximab

26-02-2013

The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Stagnant treatment future seen for inherited orphan blood diseases

23-01-2013

Generally unimpressive treatment line-ups combined with weak product pipelines will lead to modest growth…

CinryzeMarkets & MarketingPharmaceuticalRare diseasesViroPharma

Teijin debuts Ipsen's Somatuline in Japan; Galenica deal for Maltofer and Uro-Vaxom in China

18-01-2013

Teijin Pharma, the core company of the Japanese Teijin Group (TYO: 3401) health care business, and French…

Asia-PacificChina Medical SystemGalenicaIpsenLicensingMaltoferMarkets & MarketingPharmaceuticalRare diseasesSomatulineTeijinUro-VaxomVifor Pharma

Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR

25-10-2012

In the systemic lupus erythematosus (SLE) drug market, Human Genome Sciences/GlaxoSmithKline's (LSE:…

BenlystaBiotechnologyGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRare diseases

Denmark sees first launches of Almirall's Eklira Genuair and ViroPharma's Plenadren

21-09-2012

Spain's largest drugmaker, Almirall (ALM: MC), says that the Danish Health and Medicines Authority has…

AlmirallEklira GenuairEuropeMarkets & MarketingPharmaceuticalPlenadrenRare diseasesRespiratory and PulmonaryViroPharma

GlaxoSmithKline expands Fabry disease deal with Amicus, upping stake in the firm

19-07-2012

Moving forward with its foray into the rare disease sector, UK pharma giant GlaxoSmithKline (LSE: GSK)…

Amicus TherapeuticsAmigalBiotechnologyGlaxoSmithKlineMarkets & MarketingPharmaceuticalRare diseasesResearch

Elelyso: a new therapeutic option for patients with Gaucher disease

09-05-2012

The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

Benlysta continues to penetrate lupus market one year post-launch; report

08-05-2012

More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

Unmet needs in orphan diseases therapy offer opportunity for Big Pharma; report

03-05-2012

Patients suffering from orphan diseases can look forward to a wider range of drug options in the future,…

BiotechnologyMarkets & MarketingPharmaceuticalRare diseasesResearch

Drug shortages spur developments in neurometabolic treatments

17-04-2012

A prolonged gap in the neurology market following the shutdown of a Genzyme production facility is tempting…

BiotechnologyMarkets & MarketingNeurologicalPharmaceuticalRare diseasesResearch

1 to 25 of 30 results

Back to top